The performance of hims stock (NYSE: HIMS) has become a focal point for New Zealand investors seeking exposure to the rapidly evolving digital health and weight loss sectors. As of March 2026, Hims & Hers Health, Inc. presents a complex investment narrative characterized by record-breaking 2025 revenues of $2.35 billion—a 59% year-on-year surge—contrasted with a sharp 48% share price drop in early 2026 due to regulatory headwinds. While the company’s core subscription model remains robust with over 2.5 million active users, the market is currently grappling with a “tale of two tapes”: a fundamentally strong telehealth engine versus an intensifying legal battle with Novo Nordisk over compounded GLP-1 weight-loss medications. This article provides an in-depth analysis of Hims’ 2026 guidance, the $1.15 billion Eucalyptus acquisition in Australia, and the technical signals currently guiding Nasdaq traders from the South Pacific.
Understanding the New Zealand Interest in Hims Stock
For investors in New Zealand, hims stock represents one of the most visible “pure-play” telehealth investments on the Nasdaq. Although the company is headquartered in San Francisco, its recent strategic shift toward the Asia-Pacific (APAC) region has brought it closer to local interests. In February 2026, Hims announced the $1.15 billion acquisition of the Australian digital health firm Eucalyptus, which operates popular brands like Juniper and Pilot. This move is a clear signal that the company intends to replicate its high-growth U.S. model across Australia, Japan, and potentially New Zealand, diversifying its revenue away from U.S. regulatory pressures. For Kiwi investors, this international expansion offers a more familiar context for a stock that has historically been viewed as a strictly North American lifestyle play.
- Vertical Integration: Controls its own 503A sterile fulfillment capacity to manage order flow and protect margins.
- Subscription Backbone: Revenue is anchored in recurring plans with flexible cadences from 30 to 360 days.
- APAC Expansion: The Eucalyptus acquisition marks a massive entry into the Australian and Japanese markets.
- Diverse Portfolio: Specialties now include sexual health, hair loss, dermatology, mental health, and weight loss.
Vertical Integration: Controls its own 503A sterile fulfillment capacity to manage order flow and protect margins.
Subscription Backbone: Revenue is anchored in recurring plans with flexible cadences from 30 to 360 days.
APAC Expansion: The Eucalyptus acquisition marks a massive entry into the Australian and Japanese markets.
Diverse Portfolio: Specialties now include sexual health, hair loss, dermatology, mental health, and weight loss.
The Shift Toward Personalized Healthcare
The primary driver of the hims stock bull case in 2026 is the company’s successful transition from a “single-issue fix” site to a comprehensive platform for personalized medicine. By the end of 2025, over 65% of the subscriber base was utilizing personalized products, which typically command higher loyalty and better margins than generic alternatives. Tools like “MedMatch AI,” which was expanded in late 2025 to personalize anxiety treatments using millions of data points, exemplify how Hims is using technology to increase the “Monthly Online Revenue per Average Subscriber” (MORAS), which hit $83 in late 2025. This focus on personalization makes the platform stickier, as customers are less likely to churn when their treatment is tailored specifically to their biological markers.
| Feature | Details |
| Subscriber Count | Over 2.5 million (13% YoY growth) |
| Monthly Revenue/Sub | $83 (Up from $75 in 2024) |
| Personalization Rate | 65% of total membership as of Q3 FY25 |
| Gross Margin | Approximately 71.9% (Contracted from ~76%) |
Financial Results and the 2026 Revenue Guidance
The financial profile of hims stock in early 2026 is defined by high-velocity growth paired with a recent “soft” outlook that startled Wall Street. For the full year 2025, Hims reported a staggering $2.35 billion in revenue, reflecting the scaling power of its platform. However, the guidance issued in late February 2026 for the first quarter was lower than expected, with revenue projected between $600 million and $625 million. This “softness” is largely attributed to a $65 million headwind caused by shipping restrictions on compounded semaglutide (the active ingredient in Ozempic and Wegovy) as the FDA announced that branded shortages were resolving.
Profitability and Cash Flow Analysis
Despite the regulatory noise, Hims has achieved what many of its telehealth peers have not: consistent GAAP profitability. The company reported a net income of $128 million for 2025 and is guiding for an Adjusted EBITDA between $300 million and $375 million for the full year 2026. This financial stability is a critical factor for New Zealand investors who may be wary of “unprofitable tech” in a high-interest-rate environment. However, free cash flow was notably lower in Q4 2025, coming in at a negative $2.6 million due to heavy investments in the 503A manufacturing facilities and international expansion.
- 2025 Revenue: $2.35 Billion (59% increase).
- 2026 Guidance: $2.7 Billion to $2.9 Billion.
- Cash Position: Ended 2025 with $577.5 million in cash and short-term investments.
- Operating Margin: Contracted to 1.5% in Q4 2025 due to increased tech and marketing spend.
2025 Revenue: $2.35 Billion (59% increase).
2026 Guidance: $2.7 Billion to $2.9 Billion.
Cash Position: Ended 2025 with $577.5 million in cash and short-term investments.
Operating Margin: Contracted to 1.5% in Q4 2025 due to increased tech and marketing spend.
| Metric | FY 2025 Actual | FY 2026 Target |
| Total Revenue | $2.35 Billion | $2.7B – $2.9B |
| Net Income | $128 Million | Positive (not specified) |
| Adjusted EBITDA | $318 Million | $300M – $375M |
| EBITDA Margin | ~13.5% | 11% – 13% |
The GLP-1 Weight Loss Controversy and Regulatory Risk
The single biggest factor weighing on hims stock in 2026 is the regulatory uncertainty surrounding its weight-loss segment. Hims gained significant market share in 2024 and 2025 by offering compounded GLP-1 injections at a fraction of the cost of branded drugs like Ozempic. However, the “legal window” for these copycat medications relies on the FDA’s official drug shortage list. In early 2025, the FDA announced that the semaglutide shortage was largely resolved, which legally restricts compounding pharmacies from mass-producing these versions. This shift led to a massive 48% drop in share price at the start of 2026 as investors feared the loss of Hims’ most lucrative new revenue stream.
Legal Battle with Novo Nordisk and SEC Probe
Adding to the complexity, Novo Nordisk (the maker of Wegovy) filed a lawsuit against Hims in early 2026, alleging patent infringement and misleading marketing claims regarding the equivalence of compounded drugs. Furthermore, Hims disclosed in its 10-K filing that it is cooperating with an SEC investigation into its GLP-1 disclosures. While CEO Andrew Dudum has insisted that the “weight business is durable” even in a scenario where compounding is restricted, the market remains skeptical. Read more in Wikipedia.
- Compounded Semaglutide: Offered as a low-cost alternative during shortages.
- FDA Status: Resolution of shortages closes the legal compounding exemption.
- Novo Nordisk Suit: Claims Hims is mass-producing an unapproved version of its drug.
- SEC Investigation: Focused on the transparency of weight-loss related disclosures.
Compounded Semaglutide: Offered as a low-cost alternative during shortages.
FDA Status: Resolution of shortages closes the legal compounding exemption.
Novo Nordisk Suit: Claims Hims is mass-producing an unapproved version of its drug.
SEC Investigation: Focused on the transparency of weight-loss related disclosures.
| Legal/Regulatory Action | Entity | Potential Impact |
| Patent Infringement | Novo Nordisk | Potential ban on semaglutide sales |
| Disclosure Probe | SEC | Fines or restatement of financials |
| Shortage Resolution | FDA | Legal restriction on mass compounding |
| Withdrawal Notice | FDA | Forced withdrawal of oral “copycat” pills |
Strategic International Expansion: The Eucalyptus Deal
To counter the regulatory volatility in the United States, Hims has doubled down on its international strategy. The February 2026 acquisition of Eucalyptus Health for $1.15 billion is the largest in the company’s history. Eucalyptus is a dominant player in the Australian and Japanese digital health markets, and its integration allows Hims to immediately diversify its geography. This move is particularly relevant for New Zealand investors, as Eucalyptus’s brands already have a strong presence in the Tasman region, providing a blueprint for a potential “Hims NZ” launch in the near future.
Entering Australia, Japan, and the UK
The Eucalyptus acquisition isn’t just about revenue; it’s about infrastructure. Eucalyptus has built a “full-stack” healthcare model similar to Hims, with its own clinical protocols and fulfillment systems. By combining these assets, Hims & Hers can achieve economies of scale across the APAC and European regions. CFO Yemi Okupe has noted that while these international markets may run at breakeven in the near term, they are expected to become “meaningful growth and profitability vectors” as the company optimizes its global supply chain.
- Acquisition Cost: $1.15 Billion (announced Feb 2026).
- Key Brands: Includes Juniper (weight loss), Pilot (men’s health), and Kin (fertility).
- New Markets: Australia, Japan, United Kingdom, and Canada.
- Strategic Goal: Reducing dependency on U.S. domestic regulations.
Acquisition Cost: $1.15 Billion (announced Feb 2026).
Key Brands: Includes Juniper (weight loss), Pilot (men’s health), and Kin (fertility).
New Markets: Australia, Japan, United Kingdom, and Canada.
Strategic Goal: Reducing dependency on U.S. domestic regulations.
| Market | Status | Primary Brands |
| United States | Mature/Core | Hims, Hers |
| United Kingdom | Scaling | Hims, ZAVA |
| Australia | New (Acquisition) | Juniper, Pilot, Kin |
| Japan | New (Acquisition) | Eucalyptus Brands |
Analyst Ratings and Price Targets for 2026
The professional consensus on hims stock is currently a “Hold,” reflecting the extreme divide between the company’s fundamental strength and its regulatory risks. As of March 2026, the stock is trading around $16.48, a significant retracement from its 2025 highs above $70. Analysts from major firms like Citigroup and TD Cowen recently slashed their price targets, citing “regulatory uncertainties” in the weight-loss segment as a primary overhang on the stock. However, some bulls like Morgan Stanley maintain targets as high as $40, arguing that the market is overreacting to the GLP-1 risks while ignoring the massive growth in core categories like hair loss and mental health.
Technical Analysis and Market Sentiment
Technical indicators for HIMS suggest a highly volatile period ahead. The stock currently holds a “Beta” of 2.47, meaning it moves nearly two and a half times as much as the broader market. While a “buy signal” was issued by some technical models in late February 2026 after a pivot bottom, long-term moving averages remain in a general “sell” signal. For New Zealand investors, this means the stock is a “high risk” candidate that requires careful entry and exit strategies, particularly as it meets resistance near the $23.44 level.
- Median Price Target: $33.63 (43% potential upside).
- Consensus Rating: Hold (based on 39 analysts).
- 52-Week Range: $13.75 to $70.41.
- Market Cap: Approximately $2.54 Billion as of March 2026.
Median Price Target: $33.63 (43% potential upside).
Consensus Rating: Hold (based on 39 analysts).
52-Week Range: $13.75 to $70.41.
Market Cap: Approximately $2.54 Billion as of March 2026.
| Firm | Rating | Price Target (USD) |
| Evercore ISI | In-line | $33.00 |
| Morgan Stanley | Buy | $40.00 |
| Truist Securities | Hold | $18.00 |
| Piper Sandler | Neutral | $13.00 |
Risks to Consider for New Zealand Investors
Investing in hims stock from New Zealand carries layers of risk that go beyond standard market volatility. The most critical is the “Regulatory Cliff” regarding semaglutide. If the FDA bans the sale of compounded GLP-1s entirely, Hims could lose a segment that drove much of its 2025 growth, requiring the other specialties to grow even faster to hit its 2026 targets. Furthermore, because HIMS trades on the NYSE, Kiwi investors are exposed to currency fluctuations; a strengthening NZD against the USD would reduce the value of your investment in local terms.
Key Risk Factors in 2026
- Macroeconomic Sensitivity: Subscription models are sensitive to consumer discretionary spending; high inflation in NZ or the US could lead to increased churn.
- Insider Selling: Several top executives sold over $30 million in stock in early 2026, just weeks before an SEC investigation was made public.
- Concentration Risk: While Hims is diversifying, a large portion of its current valuation is tied to the successful navigation of the GLP-1 legal landscape.
- Marketing Costs: To maintain its 28% growth rate, Hims spent $238 million on marketing in Q4 2025 alone, indicating that customer acquisition is becoming more expensive.
Macroeconomic Sensitivity: Subscription models are sensitive to consumer discretionary spending; high inflation in NZ or the US could lead to increased churn.
Insider Selling: Several top executives sold over $30 million in stock in early 2026, just weeks before an SEC investigation was made public.
Concentration Risk: While Hims is diversifying, a large portion of its current valuation is tied to the successful navigation of the GLP-1 legal landscape.
Marketing Costs: To maintain its 28% growth rate, Hims spent $238 million on marketing in Q4 2025 alone, indicating that customer acquisition is becoming more expensive.
How to Buy Hims Stock in New Zealand
Because Hims & Hers Health, Inc. is listed on the New York Stock Exchange (NYSE), it is not available on the NZX. New Zealand residents must use a broker that provides access to the U.S. markets. Common platforms for Kiwis include Hatch, Stake, and Sharesies. Each platform has different fee structures for FX (foreign exchange) and brokerage, so it is important to compare them before committing capital to a high-volatility stock like HIMS.
Step-by-Step Guide for Local Investors
Select a Brokerage: Choose a platform like Hatch or Stake that allows for direct NYSE access.
Complete the W-8BEN: This is a mandatory US tax form that reduces the withholding tax on any potential dividends from 30% to 15%.
Fund Your Account: Transfer NZD and convert it to USD. Be aware of the “FX spread” fee charged by your broker.
Analyze the Technicals: Given HIMS’ high volatility, consider using a “Limit Order” rather than a “Market Order” to ensure you buy at your desired price point.
Monitor the SEC Probe: Stay updated on the ongoing SEC and FDA developments, as these will likely trigger the largest price movements in 2026.
Future Growth Catalysts to Watch
Despite the current headwinds, several catalysts could drive hims stock back toward its 2025 highs. The first is the successful integration of Eucalyptus. If Hims can prove that it can scale profitably in Australia and Japan, the market will likely assign a higher multiple to the stock for its international resilience. Secondly, the company’s expansion into proactive and preventative care—such as at-home lab testing and multi-cancer early detection tests with GRAIL—represents a multi-billion dollar opportunity that is entirely independent of the weight-loss controversy.
Expansion into Longevity and Diagnostics
In late 2025, Hims launched its “Labs” diagnostic arm, allowing customers to track key biomarkers over time and receive doctor-developed action plans. This shift toward “proactive” health moves Hims into the longevity market, a sector favored by Gen Z and Millennial audiences. If Hims can successfully upsell its 2.5 million subscribers into these diagnostic services, it could significantly boost its “Lifetime Value” per customer without increasing marketing spend.
- Diagnostic Testing: Integrated at-home tests for testosterone, heart health, and nutrition.
- AI Personalization: Continued rollout of MedMatch AI across all categories.
- International Break-even: Achieving profitability in the UK and Australia markets by late 2026.
- Hormonal Support: Scaling menopause and perimenopause offerings on the Hers platform toward $1 billion in revenue.
Diagnostic Testing: Integrated at-home tests for testosterone, heart health, and nutrition.
AI Personalization: Continued rollout of MedMatch AI across all categories.
International Break-even: Achieving profitability in the UK and Australia markets by late 2026.
Hormonal Support: Scaling menopause and perimenopause offerings on the Hers platform toward $1 billion in revenue.
Final Thoughts on Hims Stock
Hims & Hers Health remains one of the most dynamic and controversial stories in the 2026 stock market. The company has proven it can build a powerful, profitable engine with $2.35 billion in revenue and a loyal subscriber base of 2.5 million people. For New Zealand investors, the Eucalyptus acquisition provides a tangible local connection and a path for geographic diversification. However, the “GLP-1 storm”—comprising FDA shortage resolutions, a Novo Nordisk lawsuit, and an SEC probe—presents a significant technical and legal hurdle that has correctly caused a reassessment of the stock’s valuation. While the core business is growing “like a weed,” HIMS should be viewed as a high-risk growth asset that requires a high tolerance for volatility and a close watch on the U.S. regulatory landscape.
Hims Stock FAQ
What is the ticker symbol for Hims?
Hims & Hers Health, Inc. trades on the New York Stock Exchange (NYSE) under the ticker symbol HIMS.
Is Hims stock profitable?
Yes, the company achieved full-year GAAP profitability in 2024 and 2025. It reported a net income of $128 million for the 2025 fiscal year.
Why did Hims stock crash in early 2026?
The stock dropped 48% due to a combination of a softer-than-expected Q1 2026 revenue guidance, an SEC investigation into GLP-1 disclosures, and the resolution of the FDA’s drug shortage list for semaglutide.
What is the Eucalyptus acquisition?
In February 2026, Hims announced the $1.15 billion acquisition of Eucalyptus, an Australian digital health company, to expand its presence in Australia, Japan, and the UK.
Does Hims sell Ozempic?
No, Hims does not sell branded Ozempic. It provides access to “compounded semaglutide,” which contains the same active ingredient but is manufactured by compounding pharmacies.
Is the FDA banning Hims weight loss drugs?
As of March 2026, the FDA hasn’t “banned” them, but the resolution of branded semaglutide shortages has legally restricted the ability of compounding pharmacies to mass-produce copies.
Who is the CEO of Hims?
The company was co-founded and is currently led by Andrew Dudum, who serves as the Chief Executive Officer.
Can I buy Hims stock from New Zealand?
Yes, you can buy HIMS stock using New Zealand-based brokerages like Hatch, Stake, or Sharesies that offer access to the U.S. stock markets.
What is the analyst price target for HIMS?
The median 12-month price target is approximately $33.63, though individual analyst targets range from $13.00 to $85.00.
Does Hims pay a dividend?
No, Hims & Hers Health does not currently pay a dividend. It reinvests its cash flow into platform scaling and international acquisitions like Eucalyptus.
